Immunotherapeutics Branch, Division of Convergence Technology Research Institute, National Cancer Center, Goyang 10408, Korea.
Eutilex Co., Ltd, Suite #1401, Daeryung Technotown 17, Gasan digital 1-ro 25, Geumcheon-gu, Seoul 08594, Korea.
Immunotherapy. 2018 Mar;10(3):221-234. doi: 10.2217/imt-2017-0133.
Chimeric antigen receptor (CAR) T cells have outstanding therapeutic potential for treating blood cancers. The prospects for this technology have accelerated basic research, clinical translation and Big Pharma's investment in the field of T-cell therapeutics. This interest has led to the discovery of key factors that affect CAR T-cell efficacy and play pivotal roles in T-cell immunology. Herein, we introduce advances in adoptive immunotherapy and the birth of CAR T cells, and review CAR T-cell studies that focus on three important features: CAR constructs, target antigens and T-cell phenotypes. At last, we highlight novel strategies that overcome the tumor microenvironment and circumvent CAR T-cell side effects, and consider the future direction of CAR T-cell development.
嵌合抗原受体 (CAR) T 细胞在治疗血液癌症方面具有突出的治疗潜力。这项技术的前景加速了基础研究、临床转化和大型制药公司在 T 细胞治疗领域的投资。这种兴趣促使人们发现了影响 CAR T 细胞疗效的关键因素，并在 T 细胞免疫学中发挥了关键作用。在此，我们介绍了过继免疫疗法和 CAR T 细胞的诞生的进展，并回顾了专注于三个重要特征的 CAR T 细胞研究：CAR 构建体、靶抗原和 T 细胞表型。最后，我们强调了克服肿瘤微环境和规避 CAR T 细胞副作用的新策略，并考虑了 CAR T 细胞发展的未来方向。
